A Clinical trial on vedigara silasathu parpam in the management of Azhal neerchurukku (Urinary tract infection) among patients attending OPD and IPD of Government Siddha Medical College and Hospital, Palayamkottai

A Prospective open labelled single arm non randomized single centric phase II clinical trial on vedigara silasathu parpam in the management of Azhal neerchurukku (Urinary tract infection) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/068156

Enrollment

Registered

2024-05-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: VEDIGARA SILASATHU PARPAM: DOSAGE: 130 mgs Twice a day orally for 10 days Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having symptoms with burning micturition/ dysuria, fever with chills (less than 1040 F), frequency of micturition, hematuria, pain over the suprapubic region, and low back pain. (Above all any three symptoms present they will be included in clinical trial). 2.Patients who are willing to go for urine culture & undergo routine blood investigation. 3.Patients with urine culture significant for bacteria or fungus (eg.Escherichiacoli, klebsiella, enterococci, proteusmirablis staphy lococci etc……)

Exclusion criteria

Exclusion criteria: 1.Pregnant 2.Lactating mother 3.Recent malignancy or radiation therapy 4.Patients considered unreliable by the investigator(e.g., drug addiction, alcohol abuse) 5.H/O Sexually transmitted disease 6.Renal calculus 7.Hydronephrosis 8.Medical renal disease 9.Hyper pyrexia above 104 F.

Design outcomes

Primary

Measure	Time frame
The outcome will be aimed at reducing the symptoms of Azhal neerchurukku and to evaluate the therapeutic efficacy of clinical trial drug (vedigara silasathu parpam)Timepoint: 10 days	—

Secondary

Measure	Time frame
1.To collect various aspects of Azhal neerchurukku in Siddha literatures 2.To evaluate physico chemical ,phytochemical and biochemical characters of vedigara silasathu parpam. 3.To evaluate safety profile for assessing acute and subacute toxicity of trial drug vedigara silasathu parpam. 4.To study anti microbial activity of vedigara silasathu parpam against various pathogenic microorganism . 5.To evaluate pharmacological analysis of vedigara silasathu parpam. 6.Study about the prevalence of Azhal neerchurukku in relation between diet and lifestyle 7.To evaluate Siddha parameters(including envagai thervu) changes in Azhal neerchurukku during the study period 8.To evaluate modern parametric changes in Azhal neerchurukku 9.To evaluate the efficacy of Vedigara silasathu parpam on Azhal neerchurukku by the Bio statistical analysis.Timepoint: 6 months	—

Measure

Time frame

1.To collect various aspects of Azhal neerchurukku in Siddha literatures 2.To evaluate physico chemical ,phytochemical and biochemical characters of vedigara silasathu parpam. 3.To evaluate safety profile for assessing acute and subacute toxicity of trial drug vedigara silasathu parpam. 4.To study anti microbial activity of vedigara silasathu parpam against various pathogenic microorganism . 5.To evaluate pharmacological analysis of vedigara silasathu parpam. 6.Study about the prevalence of Azhal neerchurukku in relation between diet and lifestyle 7.To evaluate Siddha parameters(including envagai thervu) changes in Azhal neerchurukku during the study period 8.To evaluate modern parametric changes in Azhal neerchurukku 9.To evaluate the efficacy of Vedigara silasathu parpam on Azhal neerchurukku by the Bio statistical analysis.Timepoint: 6 months

—

Countries

India

Contacts

Public ContactProf Dr T Komalavalli

Government Siddha Medical College and Hospital

Siddhadrgs21@gmail.com9345600723

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026